NPS Pharmaceuticals, Inc. (NPSP) Misses Q1 EPS by 4c; Trims Top End of FY Gattex/Revestiv Sale Outlook

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) reported Q1 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $44.04 million versus the consensus estimate of $48.3 million.

2014 Financial Guidance

The company is revising its full-year 2014 Gattex/Revestive net sales guidance to a range of $100 to $110 million representing more than 200% year-over-year growth. The company’s previous net sales guidance was $110 million to $120 million.

The company continues to expect full-year 2014 operating expenses, excluding the impact of share-based compensation and cost of goods sold, to be between $180 and $200 million.

For earnings history and earnings-related data on NPS Pharmaceuticals, Inc. (NPSP) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
• Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance